Endothelial dysfunction, atherosclerosis and diabetes

Acta Medica Austriaca

Volumn 26, Issue 5, 1999, Pages 148-153

  Najemnik, Claudia ^a   Sinzinger, H ^a   Kritz, H ^b  

^a Dept Nucl Med City Hosp V ^*

^b Rehabilitationcenter Engelsbad BVA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; LIPOPROTEIN; NITRIC OXIDE;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; DIABETES CONTROL; DIABETES MELLITUS; DIABETOGENESIS; ENDOTHELIUM LESION; HUMAN; PROTEIN MODIFICATION; REVIEW; SMOKING CESSATION;

ARTERIOSCLEROSIS; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPOPROTEINS; NITRIC OXIDE; PROGNOSIS; RISK FACTORS;

EID: 0032725703     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, Takahashi K, Shichiri M, Horiuchi S: Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 1995;230:408-415.
2. Balon TW, Nadler JL: Evidence that nitric oxide increases glucose transport in skeletal muscle. J Appl Physiol 1997;82:359-363.
3. Baron AD, Steinberg HO: Endothelial function, insulin sensitivity, and hypertension. Circulation 1997;96:725-726.
4. Bierman E: Geroge Lyinan Duff Memorial Lecture: atherogenesis in diabetes. Arterioscler Thromb 1992;12:647-656.
5. Brownlee M, Cerami A, Vlassara H: Advanced glycation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1998;318:1315-1321.
6. Brownlee M, Vlassara H, Cerami A: Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985;34:938-941.
7. Brunzell JD, Sniderman AD, Albers JJ, Kwiterovich POJr: Apoproteins B and A-1 coronary artery disease in humans. Arteriosclerosis 1984;4:79-83.
8. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434-6438.
9. Cohen RA: Dysfunction of vascular endothelium. Circulation 1993:87 (Suppl. V):67-76.
10. Cosentino F, Lüscher TF: Maintenance of vascular integrity: role of nitric oxide and other bradykinin mediators. Eur Heart J 1995;16(K):4-12.
11. Courtiss LK, Witztum JL: Plasma apolipoproteins Al, All, B, CI, and E are glycosylated in hyperglycemic diabetic subjects. Diabetes 1985;34:452-461.
12. DeFronzo RA, Ferranini E: Insulin-resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic vascular disease. Diabetes Care 1991;14:173-194.
13. Dunbar JC, O'Leary DS, Wang G, and Wright-Richey J: Mechanisms mediating insulin-induced hypotension in rats: a role for nitric oxide and autonomic mediators. Acta Diabetol 1996;33:263-268.
14. Furchgott RF: Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activated inhibitory factor from retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte P (ed): Mechanisms of vasodilation. New York, Raven Press, 1988, pp 401-404.
15. Garcia MJ, McNamara PM, Gordon T, Kannell WB: Morbidity and mortality in diabetes in the Framingham population. Diabetes 1974;23:105-111.
16. Garg UC, Hassid A: Nitric oxide generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
17. Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MS: Low-density lipoprotein metabolism by human macrophages activated with low-density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med 1988;168:1041-1059.
18. Heitzer T, Just H, Munzel T: Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996;94:6-9.
19. Hornig B, Arakawa N, Kohler C, Drexler H: Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;97:363-368.
20. Kannell WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241:2035-2038.
21. Keen H, Jarrett RJ: The WHO multinational study of vascular disease in diabetes: 2. Macrovascular disease prevalence. Diab Care 1979;2:187-195.
22. Kim HJ, Kurup IV: Nonenzymatic glycosylation of human plasma low-density lipoprotein. Evidence for in-vitro and in-vivo glycosylation. Metab Clin Exper 1982;31:348-353.
23. King GL, Shiba T, Oliver J, Inoguchi T, Bursell SEM: Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu Rev Med 1994;45:179-188.
24. Klein RL, Lopes-Virella MF: Metabolism by human endothelial cells of very low-density lipoprotein subfractions isolated from type-I (insulin-dependent) diabetic patients. Diabetologia 1993;36:258-264.
25. Knowles RG, Moncada S: Review article: nitric oxide synthases in mammals. Biochem J 1994;298:249-258.
26. Kritz H: Vascular imaging of early atherosclerotic lesions-[11]n-HIG and 1231-fibrinogen-scintigraphy versus sonography. Vienna, Thesis, 1997.
27. Kritz H, Oguogho A, Fitscha P, Kaliman J, Rogatti W, Sinzinger H: Platelet response during prostaglandin E1-therapy in patients with NIDDM. Thromb Res 1997;87:257-261.
28. Kritz H, Oguogho A, Sinzinger H: Semotiadil, a new calcium antagonist, is a very potent inhibitor of LDL-oxidation. Thromb Res 1999; (in press).
29. Kritz H, Pidlich J, O'Grady J, Sinzinger H: Is a deficiency of prostacyclin-synthesis stimulating plasma factor associated with increased lipoprotein(a)? Prostagl Leukotr Essent Fatty Acids 1996;55:363-372.
30. Kritz H, Schmid P, Karanikas G, Rodrigues M, Sinzinger H: Detection of early atherosclerotic lesions in the carotid artery-experimental and human data. Intern J Angiology 1997;6:24-29.
31. 2-synthesis is diminished. Thromb Res 1995;6:483-489.
32. Kritz H, Sinzinger H, Fitscha P, O'Grady J: Isradipine lowers human arterial low-density lipoprotein retention in-vivo. Prostagl Leukotr Essent Fatty Acids 1998;59:305-312.
33. 2 cholesterol with coronary heart disease in noninsulin-dependent diabetics. Arteriosclerosis 1985;5:653-658.
34. Lopes-Virella MF, Virella G: Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes 1996;45(Suppl.3):40-44.
35. Lüscher TF, Noll G: Endothelial function as an end-point in interventional trials: concepts, method and current data. J Hypertens 1996;14(Suppl 2): 111-121.
36. Malinovv R: Homocysteine, vitamins and genetic interactions in vascular disease. Canadian J of Cardiology 1999;15(Suppl B):31-32.
37. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR: Impaired endothelium-dependent and -independent vasodilation in patients with type-2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35:771-776.
38. Nagasaka S, Iwamoto Y, Ishikawa S, Kuzuya T, Saito T: Efficacy of troglitazone measured by insulin-resistance index. Lancet 1997;350:184.
39. Nappo E, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, Farzati B, Giugliano D: Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999;281: 2113-2118.
40. Nathan L, Chaudhuri G: Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol 1997;37:477-515.
41. O'Grady J, Kritz H, Schmid P, Pirich Ch, Sinzinger H: Effect of isradipine on in-vivo platelet function. Thromb Res 1997;86:363-371.
42. Orekhov AN, Tertov VV, Sobenin IA, Smirnov VN, Via DP, Guevara K Jr: Sialic acid content of human low-density lipoproteins affects their interaction with cell receptors and intracellular lipid accumulation. J Lipid Res 1992;33:805-817.
43. Porte JrD, Schwartz MW: Diabetes complications: why is glucose potentially toxic? Science 1996;272:699-670.
44. Radomski MW, Palmer RM, Moncada S: The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987;148:1482-1489.
45. Reaven GM, Chen I, Jeppesen J, Maheux P, Krauss RM: Insulin-resistance and hyperinsulinemia in individuals with small, dense, low-density lipoprotein particles. J Clin Invest 1993;92:141-146.
46. Ross R: Atherosclerosis - an inflammatory disease. NEJM 1999;340; 1928-1929.
47. Sarih M, Souvannavong V, Adam A: Nitric oxide synthase induces macrophage death by apoptosis. Biochem Biophys Res Commun 1993;191: 503-508.
48. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M, Stern D: RAGE: a novel cellular receptor for advanced glycation end-products. Diabetes 1996;45(Suppl 3):77-80.
49. Schmidt AM, Van SD, Stern DM. The dark side of glucose. Nature Med 1995;1:1002-1004.
50. 125I-LDL-recepior binding by isradipine in normo-and hypercholesterolemic rabbits in-vivo. Prostaglandins 1996;52:77-91.
51. Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJ, Odekerken DA, Stehouwer CD, Silberbusch J: Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999;22:125-132.
52. Solzbach U, Hornig B, Jeserich M, Just H: Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 1997;96:1513-1519.
53. Steinberg HO, Brechtel G, Johnson A, Fineber N, Baron AD: Insulin-mediated skeletal muscle vasodilation is nitric oxide-dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94:1172-1179.
54. Steiner G: The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. Diabetologia 1996;39:1655-1661.
55. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA: Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996;97:22-28.
56. Uusitupa M, Niskanen L, Siitonen O, Voutilainen E, Pyorala K: Five-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 1990;82: 27-36.
57. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ: 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998;97: 237-241.
58. Wu JT: Advanced glycosylation end products: a new disease marker for diabetes and aging. J Clin Lab Anal 1993;7:252-255.